Bristol-Myers Squibb

Sector in which the organization works:


Short description of the organization and its work to control and eliminate NTDs

Bristol-Myers Squibb is a global BioPharma company whose mission is to discover, develop and deliver innovative medicines that help patients with serious diseases around the world. Areas of therapeutic focus for the company include cancer, immunology, hepatitis B and C, HIV/AIDS and cardiovascular disease. Through participation in the London Declaration on Neglected Tropical Diseases, we extend the reach of our R&D efforts into NTDs. Bristol-Myers Squibb’s involvement in the initiative reflects the company’s commitment to working with industry, governments and global health organizations to address global health issues.

As part of this coordinated effort, Bristol-Myers Squibb has provided access to proprietary compound libraries to third parties, including Drugs for Neglected Diseases initiative (DNDi), to help develop potential new medicines for targeted NTDs:

  • At the Institut Pasteur Korea, thousands of compounds from the Bristol-Myers Squibb library have been screened and over 100 compounds have been identified with potential activity against Chagas Disease and Visceral Leishmaniasis
  • Initial screening at the University of Dundee has identified 119 compounds with potential activity against Visceral Leishmaniasis
  • Bristol-Myers Squibb has recently extended its collaboration with DNDi on Chagas and Leishmaniasis and is looking to expand to identify potential clinical stage compounds with activity against helminthes.

Bristol-Myers Squibb also coordinates efforts to fight TB through its Foundation. The Bristol-Myers Squibb Foundation has a landmark agreement with the World Health Organization that aims to strengthen community-based care of tuberculosis including HIV co-infection in five African countries. Built on successful projects in Africa, the Bristol-Myers Squibb Foundation has developed a faculty offering that integrates community outreach for adherence both to TB and HIV treatment and management protocols and extends community-based approaches for education, case identification, rapid diagnosis and follow-up treatment.

In addition to collaborative efforts, Bristol-Myers Squibb is currently investigating compounds with potential activity against Dengue Fever, a disease that the WHO estimates impacts 50-100 million people each year in over 100 endemic countries.

Bristol-Myers Squibb is one of the 20 original endorsers of the London Declaration

Program Name

Collaboration to Address Neglected Tropical Diseases